vs
Side-by-side financial comparison of ClearSign Technologies Corp (CLIR) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.
Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $3.7M, roughly 1.1× ClearSign Technologies Corp). On growth, ClearSign Technologies Corp posted the faster year-over-year revenue change (522.2% vs -10.2%). Over the past eight quarters, ClearSign Technologies Corp's revenue compounded faster (82.5% CAGR vs 50.3%).
ClearSign Technologies Corporation (ClearSign) is a United States-based company that develops emission-control technology.
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
CLIR vs IRD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.7M | $3.9M |
| Net Profit | $-311.0K | — |
| Gross Margin | 21.9% | — |
| Operating Margin | -22.5% | — |
| Net Margin | -8.5% | — |
| Revenue YoY | 522.2% | -10.2% |
| Net Profit YoY | 73.3% | 53.0% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.7M | $3.9M | ||
| Q3 25 | $1.0M | $3.1M | ||
| Q2 25 | $133.0K | $2.9M | ||
| Q1 25 | $401.0K | $4.4M | ||
| Q4 24 | $590.0K | $4.3M | ||
| Q3 24 | $1.9M | $3.9M | ||
| Q2 24 | $45.0K | $1.1M | ||
| Q1 24 | $1.1M | $1.7M |
| Q4 25 | $-311.0K | — | ||
| Q3 25 | $-1.4M | $-17.5M | ||
| Q2 25 | $-1.7M | $-7.4M | ||
| Q1 25 | $-2.1M | $-8.2M | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.2M | $-7.5M | ||
| Q2 24 | $-1.9M | $-7.8M | ||
| Q1 24 | $-1.1M | $-7.1M |
| Q4 25 | 21.9% | — | ||
| Q3 25 | 35.8% | — | ||
| Q2 25 | 41.4% | — | ||
| Q1 25 | 48.9% | — | ||
| Q4 24 | 14.9% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 93.3% | — | ||
| Q1 24 | 39.7% | — |
| Q4 25 | -22.5% | — | ||
| Q3 25 | -170.1% | -269.9% | ||
| Q2 25 | -1382.0% | -309.0% | ||
| Q1 25 | -562.8% | -227.2% | ||
| Q4 24 | -282.4% | — | ||
| Q3 24 | -77.1% | -207.1% | ||
| Q2 24 | -4748.9% | -748.9% | ||
| Q1 24 | -113.6% | -450.5% |
| Q4 25 | -8.5% | — | ||
| Q3 25 | -138.9% | -566.9% | ||
| Q2 25 | -1263.2% | -257.5% | ||
| Q1 25 | -517.7% | -187.5% | ||
| Q4 24 | -197.3% | — | ||
| Q3 24 | -62.1% | -194.6% | ||
| Q2 24 | -4160.0% | -698.3% | ||
| Q1 24 | -100.5% | -415.3% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $-0.26 | $-0.25 | ||
| Q2 25 | $-0.30 | $-0.12 | ||
| Q1 25 | $-0.37 | $-0.24 | ||
| Q4 24 | $-0.18 | — | ||
| Q3 24 | $-0.20 | $-0.29 | ||
| Q2 24 | $-0.40 | $-0.30 | ||
| Q1 24 | $-0.30 | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.2M | $45.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.5M | $15.3M |
| Total Assets | $12.2M | $50.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $45.1M | ||
| Q3 25 | $10.5M | $30.8M | ||
| Q2 25 | $12.3M | $32.4M | ||
| Q1 25 | $12.9M | $41.8M | ||
| Q4 24 | $14.0M | $30.3M | ||
| Q3 24 | $14.5M | $36.6M | ||
| Q2 24 | $16.0M | $41.4M | ||
| Q1 24 | $4.6M | $47.2M |
| Q4 25 | $9.5M | $15.3M | ||
| Q3 25 | $9.1M | $6.0M | ||
| Q2 25 | $10.4M | $17.5M | ||
| Q1 25 | $12.0M | $5.1M | ||
| Q4 24 | $13.8M | $6.7M | ||
| Q3 24 | $14.8M | $34.3M | ||
| Q2 24 | $15.9M | $40.6M | ||
| Q1 24 | $4.5M | $46.1M |
| Q4 25 | $12.2M | $50.2M | ||
| Q3 25 | $12.7M | $36.1M | ||
| Q2 25 | $14.2M | $38.7M | ||
| Q1 25 | $14.5M | $48.2M | ||
| Q4 24 | $16.3M | $36.9M | ||
| Q3 24 | $17.1M | $40.4M | ||
| Q2 24 | $17.8M | $44.8M | ||
| Q1 24 | $6.6M | $51.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $-35.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.3M | $-35.3M | ||
| Q3 25 | $-1.8M | $-6.2M | ||
| Q2 25 | $-511.0K | $-10.3M | ||
| Q1 25 | $-1.1M | $-9.0M | ||
| Q4 24 | $-415.0K | $-25.6M | ||
| Q3 24 | $-1.4M | $-5.1M | ||
| Q2 24 | $-1.5M | $-7.3M | ||
| Q1 24 | $-1.0M | $-5.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-1.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -278.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
